Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H29NO3 |
Molecular Weight | 367.4813 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCOC(C(=O)OC1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=QPCVHQBVMYCJOM-UHFFFAOYSA-N
InChI=1S/C23H29NO3/c1-3-18-26-23(19-10-6-4-7-11-19,20-12-8-5-9-13-20)22(25)27-21-14-16-24(2)17-15-21/h4-13,21H,3,14-18H2,1-2H3
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/23288694
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/23288694
Propiverine is a well established antimuscarinic agent. It’s indicated in adults for the symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder syndrome or neurogenic detrusor overactivity (detrusor hyperreflexia) from spinal cord injuries, e.g. transverse legion paraplegia. As well as blocking muscarinic receptors in the detrusor muscle, the drug also inhibits cellular calcium influx, thereby diminishing muscle spasm. Overdose with the muscarinic receptor antagonist propiverine hydrochloride can potentially result in central anticholinergic effects, e.g. restlessness, dizziness, vertigo, disorders in speech and vision and muscular weakness. Moreover, severe dryness of mucosa, tachycardia and urinary retention may occur.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094109 Sources: http://www.ncbi.nlm.nih.gov/pubmed/26676219 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Detrunorm Approved UseTablets & capsules: Treatment of urinary incontinence, urgency and frequency in patients with idiopathic detrusor overactivity (overactive bladder).
Tablets only: Neurogenic detrusor overactivity (detrusor hyperrefexia) from spinal cord injuries, e.g. transverse lesion paraplegia. |
|||
Primary | Detrunorm Approved UseTablets & capsules: Treatment of urinary incontinence, urgency and frequency in patients with idiopathic detrusor overactivity (overactive bladder).
Tablets only: Neurogenic detrusor overactivity (detrusor hyperrefexia) from spinal cord injuries, e.g. transverse lesion paraplegia. |
Sample Use Guides
Adults: Tablets: One 15 mg tablet twice a day, which may be increased to three
times a day. Some patients may respond to one 15 mg tablet a day. For neurogenic detrusor overactivity: One 15 mg tablet three times a day; this may be increased
to four times a day (maximum recommended daily dose). Capsules: One 30 mg capsule daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/8133908
propiverine (3-10 uM) inhibited carbachol-induced contractions in the presence of verapamil and Ca(2+)-induced contractions in excess K+ medium containing atropine, suggesting it has both anticholinergic and Ca2+ channel blocking actions
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
||
|
WHO-ATC |
G04BD06
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
||
|
WHO-VATC |
QG04BD06
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
||
|
NCI_THESAURUS |
C29698
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
PROPIVERINE
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
PRIMARY | |||
|
60569-19-9
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
PRIMARY | |||
|
100000081380
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
PRIMARY | |||
|
SUB10114MIG
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
PRIMARY | |||
|
4942
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
PRIMARY | |||
|
DTXSID5048265
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
PRIMARY | |||
|
468GE2241L
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
PRIMARY | |||
|
C66491
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
PRIMARY | |||
|
5020
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
PRIMARY | |||
|
DB12278
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
PRIMARY | |||
|
2300
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
PRIMARY | |||
|
m9215
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
PRIMARY | Merck Index | ||
|
C015586
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL1078261
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
PRIMARY | |||
|
55175
Created by
admin on Fri Dec 15 16:35:59 GMT 2023 , Edited by admin on Fri Dec 15 16:35:59 GMT 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)